News
The state will continue to fund the LOEWE Center "Frankfurt Cancer Institute" – twelve million euros are planned for the next two years.

On Monday, November 10, Science Minister Timon Gremmels presented the funding certificate to Prof. Florian Greten, spokesperson of the LOEWE Center FCI and director of the Georg-Speyer House in Frankfurt, at a formal ceremony. Due to its significant achievements in cancer research, the LOEWE Center "Frankfurt Cancer Institute" (FCI), established in 2019, will continue to receive state funding in 2026 and 2027.
"With the Frankfurt Cancer Institute, the participating research institutions, with the support of LOEWE, have created an internationally renowned and exceptionally well-connected center for cancer research. We are very proud of this," said Science Minister Timon Gremmels. "The research at the interface between basic and applied research is unique in Germany in this constellation. By continuing to fund the LOEWE Center, we are strengthening our goal of transferring the research association to federal and state funding. We have been supporting this since 2019 with a total of 42 million euros to date."
Professor Michael Huth, Vice President for Transfer at Goethe University, emphasizes: "At the Frankfurt Cancer Institute, under the direction of Professor Florian Greten, we work together with our non-university partners and industry to translate findings from excellent basic research into clinical trials of innovative cancer therapies. This close collaboration characterizes both Goethe University's strategy and its recipe for success in conducting excellent research for the benefit of society. This funding will now ensure the continued success of this research."
At the FCI, under the leadership of Goethe University Frankfurt, physicians and scientists from the Georg Speyer House, the Max Planck Institute for Heart and Lung Research, the Paul Ehrlich Institute and the German Red Cross Blood Donation Service - Institute of Transfusion Medicine and Immunohematology, together with other partners, are researching the mechanisms of tumor development, resistance formation and new therapies.